Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Philippines | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Venezuela | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Philippines

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Venezuela | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Novartis Foundation | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About
      • Novartis in Philippines
      • Strategy
      • Diversity and Inclusion
      • People and Culture
      • Products
      • Country Leadership Team
      • Contact
      About
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient resources
      • Products
      • Adverse Event Reporting
      Patients and Caregivers
    • Healthcare Professionals
      • Healthcare professional country resource
      • Products
      • Novartis Pipeline
      • Adverse Event Reporting
      • Novartis Clinical Trials
      Healthcare Professionals
    • ESG
      • Ethical Behavior
        • Code of Ethics
        • SpeakUp
      • Ethics, Risk and Compliance
      • Access
      • Environmental Sustainability
      • Global Health
      ESG
    • News
      • News Archive
      • Stories
      • Contacts
      News
    • Careers
      • Career Search
      • Meet the teams
      • Personal Growth
      • Early Talent
      • How We Work
      • Well-being
      • Diversity and Inclusion
      • Career Programs
      • Awards and Recognition
      Careers
    • Coronavirus
      Coronavirus
    Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Release
  • Stories
icon
News Archive Navigation Language
  • English
  • French
  • German

July 2022

  • Media ReleaseJul 27, 2022
    Novartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy life
    Psoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help their…
  • Media ReleaseJul 11, 2022
    Philippine FDA approves Novartis advanced breast cancer treatment, alpelisib
    The Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…

June 2022

  • Media ReleaseJun 21, 2022
    Survey reveals heavy disease burden of psoriasis among Filipinos
    Filipinos with moderate-to-severe psoriasis experience significant negative impact on their quality of life, psychological and emotional wellbeing, and productivity.  This was revealed by a…

May 2022

  • Media ReleaseMay 10, 2022
    Novartis Philippines launches PIK3CA Testing Program for Breast Cancer
    Stakeholder officials signed the formal agreement to implement the Novartis PIK3CA Testing Program for advanced Breast Cancer patients. Photo shows (from left): Ms.…
  • Media ReleaseMay 06, 2022
    Survey reveals delayed diagnosis, heavy disease burden among Filipinos with axial spondyloarthritis
    On average, Filipinos with axial spondyloarthritis (axSpA) are diagnosed 5.8 years after developing the disease. axSpA has significant functional, psychosocial and economic impact on patients,…

February 2022

  • Media ReleaseFeb 15, 2022
    World Cancer Day 2022: Novartis committed to helping close the gap in cancer care
    In observance of World Cancer Day, Novartis reiterated its commitment to enhancing access to innovative cancer treatments. World Cancer Day is observed on February 4 of every year. Its theme for…

January 2022

  • Media ReleaseJan 27, 2022
    Indonesia, Philippines & Vietnam: Building on lessons learned to enhance eyecare services beyond COVID-19
    Collaboration to Preserve Sight partners from Indonesia, Vietnam and the Philippines gathered anew in a virtual forum titled “How can 2030 In Sight support eye health beyond Covid?” Convened by the…
  • Media ReleaseJan 20, 2022
    Novartis Healthcare Philippines recognized as a Top Employer for the second consecutive year
    Novartis Healthcare Philippines has been officially recognized by the Top Employers Institute as a Top Employer 2022 in the Philippines. To become recognized as a Top Employer, an organization must…
  • Media ReleaseJan 12, 2022
    IAPB, Perdami, NCSP, VRSP, FHF & Novartis join forces to provide eyecare services during the pandemic
    IAPB, Novartis and their Collaboration to Preserve Sight partners came together in a virtual roundtable discussion to share lessons learned and map the way forward in providing eyecare services in…

November 2021

  • Media ReleaseNov 20, 2021
    Novartis supports DOH goal of malaria-free PH by 2030
    In line with the country’s observance of Malaria Awareness Month this November, Novartis declared its support for the Department of Health’s target of zero malaria cases in the country by 2030. In…

October 2021

  • Media ReleaseOct 29, 2021
    Novartis, partners raise awareness on AxSpA, a debilitating spine and joint disease
    Axial Spondyloarthritis (AxSpA) is a debilitating disease that significantly impacts quality of life. Advances in early diagnosis and treatment of non-radiographic (nr-AxSpA) are crucial to fill…
  • Media ReleaseOct 01, 2021
    DOH partners with ICanServe, PHA, Novartis to promote breast cancer awareness through patient education videos
    In line with the country’s observance of Breast Cancer Awareness Month this October, the Department of Health, ICANSERVE Foundation, Philippine Hospital Association, and Novartis have joined forces…

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • › Next page

Novartis Philippines

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Footer Bottom
© 2022 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in the Philippines